<PAGE>   1
                                                        Exhibit 99

                                  RISK FACTORS

THERE IS NO ASSURANCE THAT THE PROPOSED BUSINESS OF ORBIT DESCRIBED HEREIN WILL
BE COMMERCIALLY VIABLE.  IN ADDITION, ACTUAL RESULTS OF THE DEVELOPMENT
ACTIVITIES, TECHNOLOGICAL DEVELOPMENTS, MARKET AND COMPETITIVE CONDITIONS,
RESULTS OF OPERATIONS AND OTHER FACTORS MAY REQUIRE SIGNIFICANT MODIFICATIONS
OF ALL OR PART OF THE PROPOSED BUSINESS.

         Potential Securities Act Liabilities. Current management believes the
Company has sold securities and notes without registration under the Securities
Act of 1933, as amended (the "Act"), or without qualification under the
securities (blue sky) laws of certain states.  As a result of such sales, and a
subsequent transfer of the shares by the original purchasers, the Company may
not be able to claim valid exemptions for such sales since the burden of
proving any exemption is on the Company.  Therefore, no assurances can be given
as to any liability which may result from violations of the registration or
qualifications provisions of the federal or state securities laws.  The Company
may thus may have a continuing contingent liability under the Act, the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and various
state securities laws for an undetermined amount for an undetermined period.

         Potential Corporation Law Liability.  The Company is conducting an
internal audit, which has revealed that substantial shares of the Common Stock
issued to former directors, and officers may be subject to cancellation.  This
would reduce the number of outstanding shares.  Between December 16, 1992 and
February 17, 1994, the Company issued more shares of Common Stock than it had
authorized under its Certificate of Incorporation.  Thus, approximately
18,000,000 shares of the Common Stock were "overissued."

         Potential Liability for Rescission of Dividends.  In February 1994,
the Company declared a stock dividend on a ten to one basis of the following
corporations, all of which were contemplated subsidiaries of the Company: the
TiTRODE Corporation, the Metafuse Corporation, Electronics Recovery Systems,
Inc., the Titherm Technology Corporation and Shield Safe, Inc.  In connection
with such dividends, each subsidiary was to receive a license for a particular
technology owned by the Company.  The Company's Board of Directors has
subsequently rescinded such stock dividends principally because of the concern
that such dividends may not comply with the Delaware General Corporations Law
since such dividends would strip the Company of most of its valuable assets.
It is possible that a shareholder could challenge the rescission of the
dividend and it is unclear whether a Delaware court will uphold such
rescission.  Thus, the shareholders entitled to such dividends may have a right
to seek payment of such dividend.

         Start-Up Company.  To date the Company has been engaged in the
development of technologies and intends to commercially exploit certain of its
technologies with third parties.  Until the commencement of sales or licensing
of the technologies, the Company will have no operating revenues but will
continue to incur substantial expenses.  No assurances can be given that the
Company can complete development of any technologies or that if a technology
is, or in the future may be, fully developed, that it can be manufactured by
others on a large scale basis or at a feasible cost.  Further, no assurance can
be given that any technology will receive market acceptance.  The Company is
subject to all the risks inherent in the establishment of a new enterprise and
the marketing and manufacturing of new products, many of which risks are beyond
the control of the Company.  There can be no assurances that the proposed
business of the Company described herein will be commercially viable.  In
addition, actual results of the development activities, technological
developments, market and competitive conditions, results of operation and other
factors may require significant modification of all or part of the Company's
proposed business plan.  See Item 6.  Management's Plan of Operation.

         Accumulated Deficit; Operating Losses; Going Concern.  For the year
ended December 31, 1996, the Company incurred an aggregate operating loss of
$2,027,506.  At December 31, 1996, the Company had an accumulated deficit of
$13,136,339 and a working capital deficit of $3,170,881.   The Company has a
ratio of liabilities to tangible assets of 12.9 to 1 as of December 31, 1996.
Such operating losses, accumulated deficit and the working capital deficit have
increased since such date.  The losses are principally due to (1) the Company's
unsuccessful search for license, joint venture, or partnership arrangements
with entities in industries aligned with the Company's technologies, and (2) a
lack of technological and business focus.  The report of the Company's
independent certified public accountants is qualified with regard to the
ability of the Company to continue as a going concern.





                                       1
<PAGE>   2
         Significant Defaults.  The Company is in default on a significant
number of notes that total approximately $1,150,000 in principal as of December
31, 1996.  During 1996, the Company converted $950,000 of principal and related
accrued interest amounting to $114,783 into 4,861,091 shares of common stock.
See Notes to Consolidated Financial Statements, Note 6.  Other debt is disputed
and the subject of litigation.  See Item 3.  Legal Proceedings.

         Need for Additional Financing.  The Company has limited working
capital.  The Company will need to obtain additional financing. The lack of
sufficient financing impedes the Company's ability to commercialize those
technologies, which could bring the Company revenues in the shortest time.  The
Company's business objectives may never be met due to a lack of capital.  No
assurance can be given that additional financing can be obtained, or if
obtainable, that the terms will be satisfactory to the Company.  The Company is
currently discussing future funding options with several investment parties.
See Item 6.  Management's Plan of Operation.  Liquidity and Capital Resources.

         Status of Technology.  The Company's technologies, whether patented or
unpatented, are in the development stage.  The Company's technologies are
undergoing certain feasibility studies and testing, and none has proved in
actual operations to be commercially viable, except for the TiTRODE type
electrodes.  Further, even if the Company may have to date received favorable
results in connection with such studies and tests, no assurances can be given
that any such technology will ultimately be commercially feasible.  Except for
a technology similar to the Metafusion technology, none of the technologies are
currently used on any commercial applications and it cannot be assured when, if
ever, any technologies will reach such phase.

         Risk of New Products and Technologies; Product Liability.  The
marketing of the Company's proposed products has inherent risks.  The proposed
technologies have not operated over time and under various conditions of actual
use.  Even if a proposed product is successfully developed, manufactured and
marketed, the occurrence of warranty or product's liability, or retraction of
market acceptance due to a proposed product failure or failure of such product
to operate as expected could lead to potential product liability suits.  The
Company does not currently have product liability insurance.  Development of
new technologies for manufacture is frequently subject to unforeseen expenses,
difficulties and complications and in some cases such development cannot be
accomplished.

         Product Viability.  It will be a period of time before any product
resulting from the Company's development efforts can be commercially marketed,
sold and delivered.  There can be no assurances as to when, if ever, the
proposed products can be commercially marketed, sold and delivered.  In
addition, because of such development period and other potential delays, other
companies may develop and commence production of similar products prior to the
Company commencing any joint venture activities and/or licensing.  See Item 1.
Description of Business.

         Uncertainty of Market Acceptance; Government Regulation.  There is no
assurance that the Company's proposed products will attain significant market
acceptance and generate revenues.    Generally, market acceptance of a new and
unproven technology requires substantial efforts to inform potential customers
of such new technology's distinctive characteristics.  This effort will be
crucial in marketing the Company's proposed products.  Some of the Company's
technology and the proposed products, which result therefrom, if any, may be
subject to government regulations, including federal export and trade
regulation. See Item 1.  Description of Business.

         Technological Change.  The technologies upon which any Company's
proposed products rely may undergo rapid development and change.  There can be
no assurance that a technology utilized by the Company will be competitive in
light of possible further technological developments and will not become
obsolete.

         Competition.  There are many firms, substantially all with financial
resources, experience and technical staffs larger than those of the Company
which have or may have successfully develop products which meet some of the
needs intended to be met by the Company's proposed products and some of such
companies have established strong market positions in their products.  These
competitors may respond vigorously to any threat to their established market
shares.  In addition, other companies may be developing or planning the
development of devices competitive with the Company's proposed products.

         Dependence on Licensees: Possible Joint Arrangements.  In cases where
the Company licenses a technology, the licensees will be responsible for
causing any products to be manufactured and marketed.  Therefore, in exploiting
any technology which is licensed, the Company will be dependent on the efforts
and ability (financial and otherwise) of the licensee. No assurances can be
given that definitive agreements to form joint ventures or arrangements will be
entered into, that the Company will be able to raise any funds required by any
joint venture or arrangement or that any joint venture or arrangements would
successfully exploit any technology.





                                       2
<PAGE>   3

         Risks of Foreign Operations.  Certain studies and tests of the
technologies are being conducted outside of the United States.  Certain
customers for these technologies may be outside the United States, in various
parts of the world, including Russia and Ukraine.  Thus, the Company may be
subject to the risks of operations including currency fluctuations,
import/export controls, lack of a well-defined business or legal system,
arbitrary government actions, and instability of a political system.

         Lack of Patent Protection.  Patents do not cover most of the Company's
technologies.  Of the technologies described herein, the Company's patents
cover only the electronic recovery systems and the original Metafusion Process.
Those patents held by the Company may be infringed upon by others and there can
be no assurance that the Company will be able to afford the high cost of filing
and pursuing an infringement action against any such alleged infringing party.
In addition, there can be no assurance that any particular aspect of the
Company's technologies will not be found to infringe the claims of other
existing patents.  Certain technology embodied in the patents covering the
Company's Metafusion Process may incorporate technology embodied in patents
owned by other entities.  Even if other patents infringed, Orbit may not have
the financial resources to prosecute.  The Company has also filed a number of
patent applications.  There can be no assurance that additional patents will be
issued in respect of the patent applications pending.  The Company also relies,
to a lesser extent, on trade secrets and confidential disclosure agreements to
protect its technology.  Neither the issuance of patents nor the use of trade
secrets will necessarily protect the Company from other persons using
technologies similar to those covered by the Company's patents or trade
secrets.

         Lack of Full Time Research and Development Team.  In addition to the
Company's officers, Orbit currently uses third party subcontractors and
non-affiliated laboratories to develop and review applications of its
technologies.

         Dependence on Key Individuals.  The success of the Company is
dependent upon, among other things, the services of Dr. Stephen V.  Prewett.
Dr. Prewett is Vice President - Technology Development of the Company.    The
loss of the services of Dr. Prewett for any reason could have a material
adverse effect of the prospects of the Company.

         Transactions with Management.  Over the past several years there have
been substantial transactions between the Company and members of management,
including Adrian Joseph, Tatum Singletary and Richard Wall.  These transactions
include the alleged exchange of technology developed or purchased by Mr. Joseph
for shares of Common Stock and/or the payment of shares for debt or for
services rendered to others. No assurances can be given that the value of the
technology transferred or the services rendered or other items of value
exchanged equal the value of the Common Stock transferred to such parties.
Such transfers were not approved by an independent majority of the board of
directors and thus may not have been on the same terms as if they were
transactions with unaffiliated third parties. An audit is being conducted to
review these transactions.  Management is currently attempting to rectify the
apparent misconduct in these transactions.  See Item 3. Legal Proceedings and
Item 12. Certain Relationships and Related Transactions.





                                       3